{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.4","upperLimit":"67.1","value":"41.2"},{"groupId":"OG001","lowerLimit":"12.6","upperLimit":"56.6","value":"31.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants whose best overall response (BOR) was complete response (CR) or partial response (PR) based on independent review of Efficacy and Safety Evaluation Committee. ORR was assessed according to modified response criteria based on the revised response criteria for malignant lymphoma (Cheson, 2007), skin lesion and peripheral blood disease were assessed according to clinical end points and response criteria in mycosis fungoides and Sezary syndrome (Olsen, 2011). CR: Disappearance of all evidence of disease; PR: Regression of measurable disease and no new sites.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed or refractory PTCL received E7777 9 mcg/kg/day as intravenous infusion, once daily from Day 1 through Day 5 in each treatment cycle until discontinuation or Cycle 8 (each Cycle length = 3 weeks).","id":"OG000","title":"PTCL: E7777 9 mcg/kg/Day"},{"description":"Participants with CTCL received E7777 9 mcg/kg/day as intravenous infusion, once daily from Day 1 through Day 5 in each treatment cycle until discontinuation or Cycle 8 (each Cycle length = 3 weeks).","id":"OG001","title":"CTCL: E7777 9 mcg/kg/Day"},{"description":"Participant with extranodal NK/T-cell lymphoma received E7777 9 mcg/kg/day as intravenous infusion, once daily from Day 1 through Day 5 in each treatment cycle until discontinuation or Cycle 8 (each Cycle length = 3 weeks).","id":"OG002","title":"Other: E7777 9 mcg/kg/Day"}],"paramType":"NUMBER","populationDescription":"The full analysis set (FAS) was defined as a group of participants who received at least 1 dose of the study drug.","reportingStatus":"POSTED","timeFrame":"From the date of administration of the first dose of the study drug until completion of the study or treatment discontinuation, up to approximately 3 years 1 month","title":"Objective Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}